50% of cutaneous T-cell lymphoma patients treated with 300mg IV infusion achieved objective response ...
Combined Company Commences Trading on the Nasdaq Global Market on November 16, 2017 under ...
New Preclinical Data Presented at AACR Support Best-in-Class Features of APVO436 Highlighting Reduced Cytokine ...
